Ionis Pharmaceuticals, Inc. (IONS)
Free
No email, no account, no signup.
Pulling latest news for Ionis Pharmaceuticals, Inc.…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and RNA-targeted therapeutics
Market Cap
$10.5B
Market sentiment
Sentiment has improved on the back of positive biomarker/efficacy signals from CELIA and clear, near-term regulatory catalysts, but is tempered by the missed primary endpoint and remaining uncertainty around the registrational path.
Why NEUTRAL ?
Action is set to "review" ahead of two binary FDA decisions (olezarsen sHTG and zilganersen) and to reassess the probability of registrational studies in the tau program after a missed primary endpoint despite positive secondary signals.
- Maintain a core position and consider adjusting exposure after the Jun 30 FDA decision; avoid adding aggressively until regulatory clarity and Q2 commercial/financial updates.
We're already tracking Ionis Pharmaceuticals, Inc. — here are the latest events we've registered
Recent News
- Since the last analysis, Biogen/Ionis reported topline Phase 2 CELIA results for diranersen (BIIB080) in early Alzheimer’s: robust reductions in tau-related biomarkers and signals of cognitive benefit, but the primary endpoint (dose-response on CDR-SB at week 76) was not met. Two regulatory milestones are now near-term: FDA decision on Jun 30, 2026 for TRYNGOLZA/olezarsen in severe hypertriglyceridemia (sNDA, Priority Review) and a Sep 22, 2026 PDUFA for zilganersen in Alexander disease.
Want to know how this news affects Ionis Pharmaceuticals, Inc.? Order the analysis.
Order analysis – Catalysts
30 Jun 2026 — FDA decision: TRYNGOLZA (olezarsen) in sHTG
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Ionis Pharmaceuticals, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.